Expressions of tumor stem cell markers EpCAM and CD133 in human primary hepatocellular carcinoma and their value in prognostic prediction

Tumor

Volumn 32, Issue 8, 2012, Pages 628-633

  Pan, Qun Xiong ^a   Su, Zi Jian ^a   Wang, Cong Ren ^a   Zhuang, Jian Liang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Antigens; CD133; Epithelial cell adhesion molecule; Gene expression; Liver neoplasms; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE PERIOD; PROTEIN EXPRESSION;

EID: 84865795523     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2012.08.011     Document Type: Article

References (14)

1. HORST D, KRIEGL L, ENGEL J, et al. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer[J]. Cancer Invest, 2009, 27(8):844-850.
2. LIU Q, LI J G, ZHENG X Y, et al. Expression of CD133, PAX2, ESA and GPR30 in invasive ductal breast carcinomas[J]. Chin Med J(Engl), 2009, 122(22):2763-2769.
3. CHIOU S H, YU C C, HUANG C Y, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma[J]. Clin Cancer Res, 2008, 14(13):4085-4095.
4. MAEDA S, SHINCHI H, KURAHARA H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer[J]. Br J Cancer, 2008, 98(8):1389-1397. (Pubitemid 351543575)
5. SALNIKOV A V, GLADKICH J, MOLDENHAUER G, et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients[J]. Int J Cancer, 2010, 126(4):950-958.
6. WELSCH T, KELEG S, BERGMANN F, et al. Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma[J]. Clin Exp Metastasis, 2009, 26(7): 701-711.
7. SASAKI A, KAMIYAMA T, YOKOO H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma[J]. Oncol Rep, 2010, 24(2):537-546.
8. WENT PT, LUGLI A, MEIER S, et al. Frequent EpCAM protein expression in human carcinomas[J]. Hum Pathol, 2004, 35(1):122-128. (Pubitemid 38133932)
9. DU W, JI H, CAO S, et al. EpCAM: a potential antimetastatic target for gastric cancer[J]. Dig Dis Sci, 2010, 55(8):2165-2171.
10. OSTA W A, CHEN Y, MIKHITARIAN K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy[J]. Cancer Res, 2004, 64(16):5818-5824. (Pubitemid 39095582)
11. MMITRA M, KANDALAM M, HARILAL A, et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy[J]. Mol Vis, 2012, 18:290-308.
12. YAMASHITA T, FORGUES M, WANG W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma[J]. Cancer Res, 2008, 68(5):1451-1461. (Pubitemid 351346853)
13. SHAN Y F, HUANG Y L, XIE Y K, et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status[J]. Med Oncol, 2011, 28(4):1012-1016.
14. STRÖHLEIN M A, LORDICK F, RÜTTINGER D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I / II trial[J]. Onkologie, 2011, 34(3):101-108.